537 | Samor Reality BSE SME IPO review | Dilip Davda | Avoid | IPO |
536 | Promax Power BSE SME IPO review | Dilip Davda | May apply | IPO |
535 | Dynamic Services NSE SME IPO review | Dilip Davda | Avoid | IPO |
534 | Destiny Logistics NSE SME IPO review | Dilip Davda | Avoid | IPO |
533 | Shri Venkatesh BSE SME IPO review | Dilip Davda | May apply | IPO |
532 | Jainam Ferro NSE SME IPO review | Dilip Davda | Avoid | IPO |
531 | Getalong Enterprise BSE SME IPO review | Dilip Davda | Avoid | IPO |
530 | Quadpro ITeS NSE SME IPO review | Dilip Davda | Avoid | IPO |
529 | Paras Defence and Space Technologies IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Apply | IPO |
528 | Paras Defence and Space Technologies IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
527 | Paras Defence and Space Technologies IPO Analysis by StockEdge | StockEdge | Neutral | IPO |
526 | Paras Defence and Space Technologies IPO Analysis by Religare Broking Limited | Religare Broking Limited | Neutral | IPO |
525 | Paras Defence and Space Technologies IPO Analysis by Reliance Securities | Reliance Securities | Neutral | IPO |
524 | Paras Defence and Space Technologies IPO Analysis by Marwadi Shares and Finance Limited | Marwadi Shares and Finance Ltd | Apply | IPO |
523 | Paras Defence and Space Technologies IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
522 | Paras Defence and Space Technologies IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
521 | Paras Defence and Space Technologies IPO Analysis by ICICI Direct | ICICI Direct | Neutral | IPO |
520 | Paras Defence and Space Technologies IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
519 | Paras Defence and Space Technologies IPO Analysis by Edelweiss Broking Ltd | Edelweiss Broking Ltd | Neutral | IPO |
518 | Paras Defence IPO review | Dilip Davda | May apply | IPO |
517 | Paras Defence and Space Technologies IPO Analysis by Choice Equity Broking Pvt Ltd | Choice Equity Broking Pvt Ltd | Apply | IPO |
516 | Paras Defence and Space Technologies IPO Analysis by Capital Market | Capital Market | May apply | IPO |
515 | Paras Defence and Space Technologies IPO Analysis by Canara Bank | Canara Bank | Apply | IPO |
514 | Paras Defence and Space Technologies IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
513 | Paras Defence and Space Technologies IPO Analysis by Ashika Research | Ashika Research | Neutral | IPO |
512 | Paras Defence and Space Technologies IPO Analysis by Arun Kejriwal | Arun Kejriwal | Apply | IPO |
511 | Paras Defence and Space Technologies IPO Analysis by Arihant Capital Markets Ltd | Arihant Capital Markets Ltd | Apply | IPO |
510 | Markolines Traffic BSE SME IPO review | Dilip Davda | May apply | IPO |
509 | Aditya Birla Sun Life AMC IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
508 | Aditya Birla Sun Life AMC IPO Analysis by Sharekhan Limited | Sharekhan Limited | Neutral | IPO |
507 | Aditya Birla Sun Life AMC IPO Analysis by Nirmal Bang | Nirmal Bang | Apply | IPO |
506 | Aditya Birla Sun Life AMC IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
505 | Aditya Birla Sun Life AMC IPO Analysis by ICICI Securities | ICICI Securities | Neutral | IPO |
504 | Aditya Birla Sun Life AMC IPO review | Dilip Davda | Apply | IPO |
503 | Aditya Birla Sun Life AMC IPO Analysis by Capital Market | Capital Market | May apply | IPO |
502 | Prevest Denpro IPO Analysis by Hem Securities | Hem Securities | Neutral | IPO |
501 | Prevest Denpro BSE SME IPO review | Dilip Davda | May apply | IPO |
500 | Sansera Engineering IPO Analysis by SMC Global | SMC Global | Neutral | IPO |
499 | Sansera-Engineering-Ltd-IPO-Note-Religare-Broking | Religare Broking Limited | Neutral | IPO |
498 | Sansera Engineering IPO Analysis by Marwadi Shares and Finance Limited | Marwadi Shares and Finance Ltd | Apply | IPO |
497 | Sansera Engineering IPO Analysis by Kotak Securities | Kotak Securities | Neutral | IPO |
496 | Sansera-Engineering IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
495 | Sansera Engineering IPO Analysis by ICICI Direct | ICICI Direct | Neutral | IPO |
494 | Sansera Engineering IPO review | Dilip Davda | Apply | IPO |
493 | Sansera Engineering IPO Analysis by Choice Equity Broking Pvt Ltd | Choice Equity Broking Pvt Ltd | Apply | IPO |
492 | Sansera Engineering IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
491 | Sansera Engineering IPO Analysis by BP Equities (BP Wealth) | BP Equities (BP Wealth) | Apply | IPO |
490 | Sansera Engineering IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
489 | PlatinumOne Business BSE SME IPO review | Dilip Davda | May apply | IPO |
488 | Naapbooks BSE Startup IPO review | Dilip Davda | May apply | IPO |
487 | BEW Eng. NSE SME IPO review | Dilip Davda | May apply | IPO |
486 | Vijaya Diagnostic IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Apply | IPO |
485 | Vijaya Diagnostic IPO Analysis by InvestorGain.com | InvestorGain.com | Avoid | IPO |
484 | Vijaya Diagnostic IPO Analysis by Religare Broking Limited | Religare Broking Limited | Neutral | IPO |
483 | Vijaya Diagnostic IPO Analysis by Reliance Securities | Reliance Securities | Apply | IPO |
482 | Vijaya Diagnostic IPO Analysis by Mehta Equities | Mehta Equities | Apply | IPO |
481 | Vijaya Diagnostic IPO Analysis by Marwadi Shares and Finance Limited | Marwadi Shares and Finance Ltd | Apply | IPO |
480 | Vijaya Diagnostic IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
479 | Vijaya Diagnostic IPO Analysis by Kotak Securities | Kotak Securities | Neutral | IPO |
478 | Vijaya Diagnostic IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
477 | Vijaya Diagnostic IPO Analysis by IIFL Securities | IIFL Securities | Apply | IPO |
476 | Vijaya Diagnostic IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
475 | Vijaya Diagnostic IPO Analysis by HDFC Securities Limited | HDFC Securities Limited | Neutral | IPO |
474 | Vijaya Diagnostic IPO review | Dilip Davda | May apply | IPO |
473 | Vijaya Diagnostic IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
472 | Vijaya Diagnostic IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
471 | Vijaya Diagnostic IPO Analysis by Arihant Capital Markets Ltd | Arihant Capital Markets Ltd | Apply | IPO |
470 | SBL Infratech BSE SME IPO review | Dilip Davda | Avoid | IPO |
469 | Ami Organics IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
468 | Ami Organics IPO Analysis by StockEdge | StockEdge | Neutral | IPO |
467 | Ami Organics IPO Analysis by Motilal Oswal | Motilal Oswal | Apply | IPO |
466 | Ami Organics IPO Analysis by Marwadi Shares and Finance Limited | Marwadi Shares and Finance Ltd | Apply | IPO |
465 | Ami Organics IPO Analysis by Kotak Securities | Kotak Securities | Neutral | IPO |
464 | Ami Organics IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
463 | Ami Organics IPO review | Dilip Davda | May apply | IPO |
462 | Ami Organics IPO Analysis by Capital Market | Capital Market | May apply | IPO |
461 | Ami Organics IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
460 | Ami Organics IPO Analysis by Anand Rathi | Anand Rathi | Apply | IPO |
459 | D?U Digital NSE SME IPO review | Dilip Davda | Avoid | IPO |
458 | Chemplast Sanmar IPO Analysis by InvestorGain.com | InvestorGain.com | Avoid | IPO |
457 | Chemplast Sanmar IPO Analysis by Edelweiss Broking Ltd | Edelweiss Broking Ltd | Neutral | IPO |
456 | Chemplast Sanmar IPO review | Dilip Davda | May apply | IPO |
455 | Chemplast Sanmar IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
454 | Chemplast Sanmar IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
453 | Aptus Value Housing Finance IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Neutral | IPO |
452 | Aptus Value Housing Finance IPO Analysis by Religare Broking Limited | Religare Broking Limited | Neutral | IPO |
451 | Aptus Value Housing Finance IPO Analysis by ICICI Direct | ICICI Direct | Neutral | IPO |
450 | Aptus Value Housing Finance IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
449 | Aptus Value Housing Finance IPO Analysis by HDFC Securities Limited | HDFC Securities Limited | Neutral | IPO |
448 | Aptus Value Housing Finance IPO Analysis by Edelweiss Broking Ltd | Edelweiss Broking Ltd | Neutral | IPO |
447 | Aptus Value IPO review | Dilip Davda | May apply | IPO |
446 | Aptus Value Housing Finance IPO Analysis by Choice Equity Broking Pvt Ltd | Choice Equity Broking Pvt Ltd | May apply | IPO |
445 | Aptus Value Housing Finance IPO Analysis by Capital Market | Capital Market | May apply | IPO |
444 | Aptus Value Housing Finance IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
443 | Aptus Value Housing Finance IPO Analysis by Ashika Research | Ashika Research | Apply | IPO |
442 | Aptus Value Housing Finance IPO Analysis by Arun Kejriwal | Arun Kejriwal | Avoid | IPO |
441 | Aashka Hospitals BSE SME IPO review | Dilip Davda | May apply | IPO |
440 | Krsnaa Diagnostics IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
439 | Krsnaa Diagnostics IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
438 | Krsnaa Diagnostics IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
437 | Krsnaa Diagnostics IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
436 | Krsnaa Diagno IPO review | Dilip Davda | May apply | IPO |
435 | Krsnaa Diagnostics IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
434 | Krsnaa Diagnostics IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
433 | CarTrade Tech IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Neutral | IPO |
432 | CarTrade Tech IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
431 | CarTrade Tech IPO Analysis by Nirmal Bang | Nirmal Bang | Apply | IPO |
430 | CarTrade Tech IPO Analysis by Motilal Oswal | Motilal Oswal | Apply | IPO |
429 | CarTrade Tech IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
428 | CarTrade Tech IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
427 | CarTrade Tech IPO Analysis by ICICI Direct | ICICI Direct | Apply | IPO |
426 | CarTrade Tech IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
425 | CarTrade Tech IPO Analysis by HDFC Securities Limited | HDFC Securities Limited | Neutral | IPO |
424 | CarTrade Tech IPO Analysis by Edelweiss Broking Ltd | Edelweiss Broking Ltd | Neutral | IPO |
423 | CarTrade Tech IPO review | Dilip Davda | May apply | IPO |
422 | CarTrade Tech IPO Analysis by Capital Market | Capital Market | May apply | IPO |
421 | CarTrade Tech IPO Analysis by Canara Bank | Canara Bank | Avoid | IPO |
420 | CarTrade Tech IPO Analysis by BP Equities (BP Wealth) | BP Equities (BP Wealth) | Apply | IPO |
419 | CarTrade Tech IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
418 | CarTrade Tech IPO Analysis by Ashika Research | Ashika Research | Apply | IPO |
417 | CarTrade Tech IPO Analysis by Arun Kejriwal | Arun Kejriwal | Apply | IPO |
416 | CarTrade Tech IPO Analysis by Anand Rathi | Anand Rathi | Apply | IPO |
415 | Devyani International IPO Analysis by Sharekhan Limited | Sharekhan Limited | Neutral | IPO |
414 | Devyani International IPO Analysis by Religare Broking Limited | Religare Broking Limited | Neutral | IPO |
413 | Devyani International IPO Analysis by Prabhudas Lilladher Pvt Ltd | Prabhudas Lilladher Pvt Ltd | Apply | IPO |
412 | Devyani International IPO Analysis by Nirmal Bang | Nirmal Bang | Apply | IPO |
411 | Devyani International IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
410 | Devyani International IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
409 | Devyani International IPO Analysis by ICICI Direct | ICICI Direct | Apply | IPO |
408 | Devyani Intl IPO review | Dilip Davda | May apply | IPO |
407 | Devyani International IPO Analysis by Choice Equity Broking Pvt Ltd | Choice Equity Broking Pvt Ltd | Apply | IPO |
406 | Devyani International IPO Analysis by Capital Market | Capital Market | May apply | IPO |
405 | Devyani International IPO Analysis by Canara Bank | Canara Bank | Apply | IPO |
404 | Devyani International IPO Analysis by BP Equities (BP Wealth) | BP Equities (BP Wealth) | Apply | IPO |
403 | Devyani International IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
402 | Devyani International IPO Analysis by Ashika Research | Ashika Research | Apply | IPO |
401 | Devyani International IPO Analysis by Arun Kejriwal | Arun Kejriwal | Apply | IPO |
400 | Devyani International IPO Analysis by Angel One | Angel One | Apply | IPO |
399 | Windlas Biotech IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
398 | Windlas Biotech IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
397 | Windlas Bio IPO review | Dilip Davda | May apply | IPO |
396 | Windlas Biotech IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
395 | Exxaro Tiles IPO Analysis by SMC Global | SMC Global | Apply | IPO |
394 | Exxaro Tiles IPO Analysis by Reliance Securities | Reliance Securities | Neutral | IPO |
393 | Exxaro Tiles IPO Analysis by JM Financial Institutional Securities | JM Financial Institutional Securities | Neutral | IPO |
392 | Exxaro Tiles IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
391 | Exxaro Tiles IPO review | Dilip Davda | May apply | IPO |
390 | Exxaro Tiles IPO Analysis by Capital Market | Capital Market | May apply | IPO |
389 | Exxaro Tiles IPO Analysis by Canara Bank | Canara Bank | Apply | IPO |
388 | Exxaro Tiles IPO Analysis by AUM Capital Ltd | AUM Capital Ltd | Neutral | IPO |
387 | Exxaro Tiles IPO Analysis by Arun Kejriwal | Arun Kejriwal | May apply | IPO |
386 | Exxaro Tiles IPO Analysis by Arihant Capital Markets Ltd | Arihant Capital Markets Ltd | Apply | IPO |
385 | Nuvoco IPO Analysis by InvestorGain.com | InvestorGain.com | Avoid | IPO |
384 | Nuvoco IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
383 | Nuvoco IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
382 | Nuvoco IPO Analysis by IDBI Capital | IDBI Capital | Apply | IPO |
381 | Nuvoco IPO Analysis by ICICI Direct | ICICI Direct | Neutral | IPO |
380 | Nuvoco IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
379 | Nuvoco IPO Analysis by HDFC Securities Limited | HDFC Securities Limited | Neutral | IPO |
378 | Nuvoco IPO Analysis by Edelweiss Broking Ltd | Edelweiss Broking Ltd | Neutral | IPO |
377 | Nuvoco Vistas IPO review | Dilip Davda | May apply | IPO |
376 | Nuvoco IPO Analysis by Capital Market | Capital Market | Avoid | IPO |
375 | Nuvoco IPO Analysis by Canara Bank | Canara Bank | Apply | IPO |
374 | Nuvoco IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
373 | Nuvoco IPO Analysis by Arun Kejriwal | Arun Kejriwal | May apply | IPO |
372 | Nuvoco IPO Analysis by Angel One | Angel One | Apply | IPO |
371 | Network People NSE SME IPO review | Dilip Davda | May apply | IPO |
370 | Gretex Corp BSE SME IPO review | Dilip Davda | Avoid | IPO |
369 | Rex Pipes NSE SME IPO review | Dilip Davda | May apply | IPO |
368 | Rolex Rings IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Apply | IPO |
367 | Rolex Rings IPO Analysis by Reliance Securities | Reliance Securities | Apply | IPO |
366 | Rolex Rings IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
365 | Rolex Rings IPO Analysis by ICICI Direct | ICICI Direct | Apply | IPO |
364 | Rolex Rings IPO Analysis by Hem Securities | Hem Securities | Apply | IPO |
363 | Rolex Rings IPO review | Dilip Davda | Apply | IPO |
362 | Rolex Rings IPO Analysis by Capital Market | Capital Market | May apply | IPO |
361 | Rolex Rings IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
360 | Paytm IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
359 | Paytm IPO Analysis by Religare Broking Limited | Religare Broking Limited | Neutral | IPO |
358 | Paytm IPO Analysis by Reliance Securities | Reliance Securities | Apply | IPO |
357 | Paytm IPO Analysis by Multi-Act Equity Consultancy Pvt Ltd | Multi-Act Equity Consultancy Pvt Ltd | Neutral | IPO |
356 | Paytm IPO Pre-Listing Analysis by Macquarie Research | Macquarie Research | Avoid | IPO |
355 | Paytm IPO Analysis by ICICI Direct | ICICI Direct | Neutral | IPO |
354 | One 97 Commu (PayTM) IPO review | Dilip Davda | May apply | IPO |
353 | One 97 Communications Limited IPO Analysis by Capital Market | Capital Market | Neutral | IPO |
352 | Paytm IPO Analysis by Canara Bank | Canara Bank | Apply | IPO |
351 | Paytm IPO Analysis by Axis Securities Limited | Axis Securities Limited | Neutral | IPO |
350 | Paytm IPO Analysis by Axis Capital | Axis Capital | Neutral | IPO |
349 | Paytm IPO Analysis by Ashika Research | Ashika Research | Neutral | IPO |
348 | Paytm IPO Analysis by Arihant Capital Markets Ltd | Arihant Capital Markets Ltd | Apply | IPO |
347 | Paytm IPO Analysis by Anand Rathi | Anand Rathi | Apply | IPO |
346 | Tatva Chintan Pharma IPO Analysis by Ventura Securities Limited | Ventura Securities Limited | Apply | IPO |
345 | Tatva Chintan Pharma IPO Analysis by InvestorGain.com | InvestorGain.com | Apply | IPO |
344 | Tatva Chintan Pharma IPO Analysis by Sharekhan Limited | Sharekhan Limited | Neutral | IPO |
343 | Tatva Chintan Pharma IPO Analysis by Reliance Securities | Reliance Securities | Apply | IPO |
342 | Tatva Chintan Pharma IPO Analysis by Motilal Oswal | Motilal Oswal | Apply | IPO |
341 | Tatva Chintan Pharma IPO Analysis by KR Choksey Securities Ltd | KR Choksey Securities Ltd | Apply | IPO |
340 | Tatva Chintan Pharma IPO Analysis by Investmentz Ltd | Investmentz Ltd | Apply | IPO |
339 | Tatva Chintan IPO review | Dilip Davda | Apply | IPO |
338 | Tatva Chintan Pharma IPO Analysis by Capital Market | Capital Market | May apply | IPO |
First Prev 2 of 4 Next Last |